Redbiotec and GE Healthcare complete CMV vaccine alliance

Redbiotec has completed a project with GE Healthcare aimed at accelerating the creation of new vaccines against cytomegalovirus (CMV).

The firm was able to successfully apply its unique expertise and innovative technology platform to help develop a novel process for the production, clarification and concentration of CMV-like particles.

Their work also utilised GE Healthcare's single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system, which were developed specifically for the fast and scalable production of biopharmaceuticals such as Redbiotec's virus-like particle.

Results from the study have recently been published, underlining the value of Redbiotec's rePAX platform for the development and production of new vaccines against CMV.

Christian Schaub, chief executive officer of Redbiotec, said: "Collaborations such as this project with GE Healthcare enable us to develop CMV-like particles and soluble CMV protein complexes at an industrial scale for the pre-clinical and clinical trials of vaccines."

Redbiotec is based in Switzerland and is also currently working on vaccines for conditions such as human papillomavirus and influenza.